🇺🇸 FDA
Pipeline program

SODIUM LAURILSULFATE, Canoderm 5 % kräm, Aqua ad iniectabilia Braun Lösungsmittel zur Herstellung von Parenteralia, Propyless 200 mg/g kutan emulsion, Miniderm 20 % kräm, CARBAMIDE, COMBINATIONS

CSCI-SKT-B1001

Phase 2 small_molecule active

Quick answer

SODIUM LAURILSULFATE, Canoderm 5 % kräm, Aqua ad iniectabilia Braun Lösungsmittel zur Herstellung von Parenteralia, Propyless 200 mg/g kutan emulsion, Miniderm 20 % kräm, CARBAMIDE, COMBINATIONS for Atopic dermatitis is a Phase 2 program (small_molecule) at Nordic Group B.V. with 1 ClinicalTrials.gov record(s).

Program details

Company
Nordic Group B.V.
Indication
Atopic dermatitis
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials